KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBITDA Margin: 2018-2025

Historic EBITDA Margin for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to -3.36%.

  • BioNTech SE's EBITDA Margin fell 1836.00% to -3.36% in Q3 2025 from the same period last year, while for Sep 2025 it was -28.41%, marking a year-over-year increase of 475.00%. This contributed to the annual value of -47.77% for FY2024, which is 6585.00% down from last year.
  • Latest data reveals that BioNTech SE reported EBITDA Margin of -3.36% as of Q3 2025, which was up 97.94% from -162.96% recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's EBITDA Margin ranged from a high of 58.08% in Q1 2022 and a low of -711.27% during Q2 2024.
  • Moreover, its 3-year median value for EBITDA Margin was -3.36% (2025), whereas its average is -120.87%.
  • As far as peak fluctuations go, BioNTech SE's EBITDA Margin tumbled by 60,262bps in 2024, and later skyrocketed by 54,831bps in 2025.
  • BioNTech SE's EBITDA Margin (Quarterly) stood at 4.30% in 2021, then soared by 88bps to 5.18% in 2022, then slumped by 491bps to 0.27% in 2023, then surged by 289bps to 3.16% in 2024, then slumped by 1,836bps to -3.36% in 2025.
  • Its last three reported values are -3.36% in Q3 2025, -162.96% for Q2 2025, and -261.93% during Q1 2025.